Table 1.
N cases and % prevalence of lifetime evaluated somatic health outcomes (N = 10,645).
| Disease area/outcome | Combined | Register-based | Self-reported |
|---|---|---|---|
| Cardio-metabolic | |||
| Ischemic heart disease | 1206 (11.3) | 1104 (10.4) | 231 (2.2) |
| Heart failure | 1174 (11.0) | 453 (4.3) | 843 (7.9) |
| Cerebrovascular disease | 1686 (15.8) | 1431 (13.4) | 760 (7.1) |
| Peripheral vascular disease | 523 (4.9) | 408 (3.8) | 157 (1.5) |
| Hypertension | 2730 (25.6) | 735 (6.9) | 2379 (22.4) |
| Obesity | 1538 (14.4) | 67 (0.6) | 1526 (14.6) |
| Type 2 Diabetes | 554 (5.2) | 385 (3.6) | 347 (3.3) |
| Autoimmune/inflammatory disease | |||
| Type 1 Diabetes | 163 (1.5) | 161 (1.5) | 46 (0.4) |
| Rheumatoid arthritis | 594 (5.6) | 163 (1.5) | 521 (4.9) |
| Psoriasis | 605 (5.7) | 195 (1.8) | 503 (4.7) |
| Inflammatory bowel disease | 243 (2.3) | 176 (1.7) | 153 (1.4) |
| Neurology | |||
| Migraine | 2207 (20.7) | 298 (2.8) | 2125 (20.0) |
| Epilepsy | 231 (2.2) | 116 (1.1) | 121 (1.2) |
| Dementia | 374 (3.5)a | 374 (3.5) | N/A |
| Parkinson disease and parkinsonism | 473 (4.4) | 472 (4.4) | 10 (0.1) |
| Sleep disorder | 1272 (11.9)a | 1272 (11.9) | N/A |
Register-based outcomes were treated as lifetime and defined based on a discharge diagnosis in the National Patient Register, the Cause of death register or disorder-specific drug dispensations. Self-report refers to questions answered as part of the SALT interview and were phrased as lifetime. Combined prevalence refers to the total number of cases identified via National Registers, self-report, or both. For details, see methods and Table S1.
aPrevalence based on register data only as there were no measures of dementia or sleep disorders available from self-report in the full SALT cohort.